LIEGE, BELGIUM, Jun 29, 2012 (BUSINESS WIRE) -- Regulatory News: MDxHealth SA (nyse euronext:MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, announced today that it has successfully raised EUR 10,000,000 million in gross proceeds through a private placement of new shares with investors in various jurisdictions. Pursuant to the private placement, MDxHealth will issue 1,996,008 new ordinary shares to Biovest Comm. VA. at an offer price of EUR 1.503 and 4,895,105 new ordinary shares to a range of other investors at an offer price of EUR 1.430 (i.e. the previous closing price of the shares).
"We are delighted to have raised this additional funding from a mix of new and existing investors who share our belief in the commercial potential of our world leading DNA methylation platform," said Jan Groen, chief executive officer of MDxHealth. "In combination with our existing cash position, these funds allow us firstly and mainly to support and scale-up a US-based sales and marketing team and, subsequently, to operate and scale-up the Company's U.S.-based CLIA-registered commercial laboratory".
The payment and delivery of the new shares is expected to take place on July 4, 2012, at which date the new shares are also expected to be admitted to listing, subject to the approval and publication of a listing prospectus. The new shares will be fully interchangeable with the existing shares on NYSE Euronext. Immediately after the closing of the private placement, MDxHealth's issued and outstanding shares will increase by 27% from 18,622,327 to 25,513,440 ordinary shares.
ING Belgium NV/SA has acted as global coordinator and joint bookrunner and Petercam NV/SA has acted as joint bookrunner in the private placement.
A listing prospectus will be available in English and French on the website of MDxHealth ( http://www.mdxhealth.com ), as from July 4, 2012. Moreover, copies of the listing prospectus will be available, without charge, at Tour 5 Giga, Avenue de l'Hopital 11, 4000 Liege, Belgium, as from July 4, 2012.
MDxHealth is a leading molecular diagnostics company that develops and commercializes epigenetic tests to support cancer treatment. The company's tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit http://www.mdxhealth.com .
Important information about forward-looking statements
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of MDxHealth, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. This press release is not an offer of securities for sale into the United States, Canada, Australia or Japan.
The new shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration. The Company does not intend to register any portion of the placing in the United States or to conduct a public offering of securities in the United States.
SOURCE: MDxHealth SA
Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70
UK: +44 20 7318 2955
Cell: +44 7968 022075